Love Maharashtra? Then you wil love Marathikatta!
Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                    Movies   Aviation   Pharma   About Us   Feedback   Links
ABE LABORATORIES BANKRUPTCY - REORGANIZATION PLAN
 


Able files recast plan with bankruptcy court 

BY OUR PHARMA CORRESPONDENT
March 25, 2006

New Jersey-based Able Laboratories has filed a proposed reorganization plan and disclosure statement relating to the plan with the US Bankruptcy Court for the district.

The plan provides for the continuation of Able's business in order for it to complete the ongoing recall of products and other measures required by the FDA, for it to assist with other government agencies with inquires regarding Able's prior operations, and to sell any remaining assets and wind down its operations.

Under the terms of the proposed plan, claims secured by collateral or rights of setoff and claims entitled to priority in payment will be paid off in full. Holders of general unsecured claims will receive a pro-rata portion of available cash, as defined by the plan.

The percentage distribution to be paid to holder of general unsecured claims is uncertain, and will depend upon the amount of general unsecured claims that are allowed and the amount of available cash. 

However, the plan allows payment of general unsecured claims in amounts of US$500 or less to be paid in full. Able added that the plan and disclosure statement provide that holders of subordinated claims, if any, will not receive any distributions unless all general unsecured claims are paid in full; Able noted it was extremely remote that general unsecured claims would be paid in full. 

Also, equity interests will not receive any distributions unless all general unsecured claims and subordinated claims are paid in full, which is again remote, and that the equity of the company has no value.

The plan will be funded from assets held by Able; these are mainly cash remaining from the sale of the majority of its assets to Sun Pharmaceutical Industries.

The plan also provides for the creation of a litigation trust to hold and assert, for the benefit of Able's creditors, certain claims and causes of action held by Able. The firm noted that the Bankruptcy Court has scheduled a hearing to approve the disclosure statement on 6th April 2006 at the US Bankruptcy Court in Trenton, New Jersey.

However, Able added that there could be no assurances that the disclosure statement would be approved, or that the Bankruptcy Court would confirm Able's plan. In addition, there could be no assurance that even if the plan is confirmed and enacted, it would achieve all of its objectives.

Able Laboratories, Inc. is a developer and manufacturer of generic pharmaceutical products in tablet, capsule, liquid and suppository dosage forms.

More related stories from Pharma


Healing prayers no cure for the ill, says study

Pulmonary hypertension drug PulmoLAR in human trial

Pharma markets in China, Korea, Mexico, Russia & Turkey gather pace

Pfizerís anxiety drug Lyrica gets EU nod

Asymmetrical breasts: A presage to cancer?

Dream to eradicate polio still far off

GlaxoSmithKline loses fluticasone case

Able files recast plan with bankruptcy court

Ranbaxy in pact with Zenotech on cancer drugs

Lupin and Aspen to form JV on TB drugs

Blood cancer drug Ceflatonin gets orphan drug status

Bangladesh to set up API park; to export drugs worth Tk 8.50 cr to Burma

Wockhard Limited: A profile
Cipla Ltd company profile

 

 

 

Auto news for auto freaks! iDrive.in
DWS community! / Cricket blog

 

Latest Stories in Pharma

 Vertex commences phase II studies for Aurora kinase inhibitor VX-680

GlaxoSmithKline starts H5N1 avian flu vaccine trials in Germany, Belgium

Novartis acquires rights for two drug leads

Serono plans major acquisitions

Samaritan to sell Amphocil in Greece

HIV infection cases fall in South India

Flu drug: Erimos, NC State University seek patent for EM-1421

HollisterStier inks pact with Prism Pharma on cardiovascular drug PM101

Erbitux approved for head and neck cancer in Europe

EPIX Pharmaceuticals merges with Predix

Avanir's involuntary emotional expression disorder (IEED) drug Neurodex gets priority review

 Death of women raises alarm on abortion pillís safety

Prestwick gets approvable letter for Xenazine for treatment of chorea with HD

Nexavar - Kidney cancer drug gets Swiss nod

Anti-rejection drug Prograf approved in US

 

Latest Stories in Pharma

Archived Pharma stories

 

Latest updates    Contact Us - Feedback    About Us